A long-acting complement-blocking infusion
Ravulizumab
A long-acting infusion that blocks part of the immune system (complement) to treat certain rare blood and kidney conditions.
What is Ravulizumab?
Ravulizumab is a specialist medicine used for rare conditions driven by an overactive part of the immune system called complement, including paroxysmal nocturnal haemoglobinuria (where red blood cells are destroyed) and atypical haemolytic uraemic syndrome (which can damage the kidneys). It works by blocking a complement protein (C5) to stop this damage. It is given as a drip into a vein every few weeks. The most important safety point is a raised risk of serious infection with meningococcal bacteria, so vaccination against meningococcus is required before treatment and people are given an alert card and advice.
Education and reference only. This is a plain-language guide to Ravulizumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Ravulizumab is a medicine used to treat certain rare conditions caused by an overactive part of the immune system known as the complement system. These include paroxysmal nocturnal haemoglobinuria, where the body destroys its own red blood cells, and atypical haemolytic uraemic syndrome, where small blood clots can damage the kidneys. It is a long-acting antibody that blocks a complement protein called C5. It is given as an infusion (a drip) into a vein, usually every few weeks, which is less often than some older treatments in the same group. It is used under specialist supervision.
How it works
The complement system is part of the immune defence, but when it is overactive it can attack the body's own cells. Ravulizumab attaches to a complement protein called C5 and stops it being activated, which prevents the chain of events that destroys red blood cells in paroxysmal nocturnal haemoglobinuria and damages small blood vessels in atypical haemolytic uraemic syndrome. Because it has been designed to last a long time in the body, it can be given as a drip every few weeks while keeping complement blocked steadily. Blocking complement also lowers a particular part of the body's defence against meningococcal bacteria, which is why vaccination is needed.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist medicine used in the UK for rare conditions such as paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, given as a long-acting drip.
Practical use
How to take Ravulizumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as an infusion (a drip) into a vein by a healthcare team, usually every few weeks.
- Make sure you have had the required meningococcal vaccination before starting, and any boosters advised.
- Carry the patient alert card you are given, and show it to any healthcare professional.
- Seek urgent help for fever, severe headache, neck stiffness, a rash or feeling very unwell, as these can signal serious infection.
- Do not stop treatment without specialist advice, as the condition can flare when treatment stops.
Weighing it up
Advantages & disadvantages of Ravulizumab
Advantages
- Effectively blocks the overactive complement that drives these rare conditions.
- Long-acting, so it is given as a drip every few weeks rather than more often.
- Can reduce red-cell destruction and protect the kidneys, depending on the condition treated.
Disadvantages
- Raises the risk of serious meningococcal infection, requiring vaccination and vigilance.
- Given as an infusion into a vein rather than as a tablet.
- Usually a long-term treatment, and stopping it can let the condition flare.
Practical use
Good to know
The single most important thing to know is that blocking complement raises the risk of serious, potentially life-threatening infection with meningococcal bacteria. Because of this, vaccination against meningococcus is required before starting (and sometimes antibiotics are given as well), and you are given a patient alert card to carry. You should seek urgent medical help for any fever, severe headache, neck stiffness, a rash or feeling very unwell, as these can be signs of meningococcal infection. Treatment is usually long term and given as a drip every few weeks. Stopping treatment, particularly in paroxysmal nocturnal haemoglobinuria, can lead to a flare of the condition, so it is only stopped with specialist advice and monitoring afterwards.
Who should not take it / use with caution
- People who have not had the required meningococcal vaccination should not start it unless given protective antibiotics, on specialist advice.
- People with an unresolved serious meningococcal infection should not start it.
- People who have had a serious allergic reaction to ravulizumab should not use it.
Monitoring
- Checking meningococcal vaccination is up to date before and during treatment.
- Watching closely for any signs of infection throughout treatment.
- Blood tests to follow the response of the condition, such as red-cell breakdown or kidney function.
Side effects
- Headache, tiredness, nausea or mild infusion reactions.
- Cold-like symptoms or other common infections.
- Rarely but seriously, meningococcal or other serious infections, which need urgent attention.
Key interactions
- There are few well-established routine medicine interactions, but tell your team about all your medicines.
- Vaccination status is the key thing to address before treatment, rather than a drug interaction.
- Other treatments that affect the immune system should be discussed with your specialist.
Available as: A solution given as an infusion (a drip) into a vein.
Answers
Ravulizumab: frequently asked questions
What is ravulizumab used for?
It is used for rare conditions driven by an overactive complement system, such as paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
Why do I need a meningococcal vaccine?
Blocking complement lowers part of your defence against meningococcal bacteria, so vaccination is required before treatment to reduce the risk of serious infection.
What signs of infection should worry me?
Seek urgent help for fever, severe headache, neck stiffness, a rash or feeling very unwell, as these can be signs of serious meningococcal infection.
How often is it given?
It is given as a drip into a vein every few weeks, which is less often than some older medicines that work in a similar way.
Can I stop it if I feel well?
No. Stopping treatment, especially in paroxysmal nocturnal haemoglobinuria, can let the condition flare, so it is only stopped with specialist advice and monitoring.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.